Tianxiang Hu

Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1‐driven leukemia/lymphomas

John K. Cowell, Haiyan Qin, Tianxiang Hu et al. · International Journal of Cancer · 2017 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies

Baohuan Cai, Yun Liu, Yating Chong et al. · Molecular Cancer · 2021 · 53 citations · Full text

Medicine, Immunology, Oncology +17

Long non-coding RNAs transcribed by ERV-9 LTR retrotransposon act in cis to modulate long-range LTR enhancer function

Tianxiang Hu, Wenhu Pi, Xingguo Zhu et al. · Nucleic Acids Research · 2017 · 45 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome

Tianxiang Hu, Qing Wu, Yating Chong et al. · Leukemia · 2018 · 40 citations · Full text

Medicine, Genetics, Oncology +16

miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the <i>BCL2L11</i> and <i>BAX</i> Proapoptotic Genes

Tianxiang Hu, Yating Chong, Sumin Lu et al. · Cancer Research · 2018 · 39 citations · Full text

Life Sciences, Molecular Biology, Oncology +17